Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q7L5N7

UPID:
PCAT2_HUMAN

ALTERNATIVE NAMES:
1-acylglycerol-3-phosphate O-acyltransferase 11; 1-acylglycerophosphocholine O-acyltransferase; 1-alkenylglycerophosphocholine O-acyltransferase; 1-alkylglycerophosphocholine O-acetyltransferase; Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; Acyltransferase-like 1; Lysophosphatidic acid acyltransferase alpha

ALTERNATIVE UPACC:
Q7L5N7; A3KBM1; Q6MZJ6; Q9NX23

BACKGROUND:
The enzyme Lysophosphatidylcholine acyltransferase 2, known for its acyltransferase and acetyltransferase functions, plays a pivotal role in converting lysophosphatidylcholine into phosphatidylcholine and in the synthesis of platelet-activating factor. This enzyme's activity is essential for the proper composition of cell membranes and for the regulation of inflammatory responses, showcasing its significance in cellular physiology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Lysophosphatidylcholine acyltransferase 2 offers a promising avenue for the development of novel therapeutic approaches. Its critical role in lipid metabolism and inflammation presents it as an attractive target for interventions in metabolic and inflammatory disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.